Eli Lilly

News

A triple dose of Novo Nordisk's GLP-1 agonist Wegovy has shown improved activity on weight loss in an obesity trial versus the current formulation.

News

After MSD's bombshell retreat from a big UK investment plan, AstraZeneca, Lilly, and Sanofi are also pressing pause on new projects.

News

Lilly has lost an appeal in a whistleblower lawsuit that alleged it had defrauded Medicaid by underpaying rebates.

News

Lilly has launched a new awareness campaign in the US, focusing on dementia, and named A-list actress Julianne Moore to front it.

News

Eli Lilly is offering AI-powered drug discovery models developed at a cost of around $1 billion to biotech companies for free.

News

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.